116 related articles for article (PubMed ID: 3064802)
41. Risks of viral transmission by blood products: current status of preventive measures.
Chaplin H; Ramos R
Mo Med; 1990 Jan; 87(1):37-40. PubMed ID: 2308574
[TBL] [Abstract][Full Text] [Related]
42. Ways to reduce the risk of transmission of viral infections by plasma and plasma products. A comparison of methods, their advantages and disadvantages.
Vox Sang; 1988; 54(4):228-45. PubMed ID: 3388821
[No Abstract] [Full Text] [Related]
43. Virus inactivation procedures: an overview.
Tedder R
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S13-4. PubMed ID: 7495960
[TBL] [Abstract][Full Text] [Related]
44. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
45. [Can virus safety of blood products be assured?].
Krusius T
Duodecim; 1994; 110(13):1227-30. PubMed ID: 7497931
[No Abstract] [Full Text] [Related]
46. Carcinoembryonic antigen: transmission by blood products.
Gitnick GL; Molnar IG
Cancer; 1978 Sep; 42(3 Suppl):1568-73. PubMed ID: 709526
[No Abstract] [Full Text] [Related]
47. [Transmission of bacterial and viral (hepatitis B virus) infections during endoscopy of the upper gastrointestinal system].
Piette M; Elewaut A
Tijdschr Gastroenterol; 1977; 20(1):57-9. PubMed ID: 888134
[No Abstract] [Full Text] [Related]
48. [Viral safety considerations in immunoglobulin preparations].
Gómez Manzano P; Escrivá CA; Salmerón García F; Alonso Verduras C
Sangre (Barc); 1997 Jun; 42(3):199-203. PubMed ID: 9381262
[No Abstract] [Full Text] [Related]
49. Blood transfusion--transmission of bacteria and some viruses.
Nurse GT
S Afr Med J; 1992 Sep; 82(3):145-6. PubMed ID: 1519129
[No Abstract] [Full Text] [Related]
50. Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion.
Couroucé AM; Pillonel J
N Engl J Med; 1996 Nov; 335(21):1609-10. PubMed ID: 8927113
[No Abstract] [Full Text] [Related]
51. Strategies to produce virus-safe blood derivatives.
Heimburger N; Karges HE
Curr Stud Hematol Blood Transfus; 1989; (56):23-33. PubMed ID: 2910651
[No Abstract] [Full Text] [Related]
52. At what stage should virus inactivation be carried out?
Dorner F; Barrett PN; Eibl J
Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
[TBL] [Abstract][Full Text] [Related]
53. Inactivation of virus in blood products.
Prodouz KN; Fratantoni JC
Transfusion; 1988; 28(1):2-3. PubMed ID: 3341059
[No Abstract] [Full Text] [Related]
54. Haematology.
O'Connor NT
Postgrad Med J; 1990 Aug; 66(778):595-611. PubMed ID: 2217028
[No Abstract] [Full Text] [Related]
55. [Prevention of hospital infection: prevention of infection by blood-borne viruses].
Yoshihara N
Kango Tenbo; 1987 Sep; 12(10):977-9. PubMed ID: 3682912
[No Abstract] [Full Text] [Related]
56. Informed consent, risk, and blood transfusion.
Kolins J; Kolins MD
J Thorac Cardiovasc Surg; 1990 Jul; 100(1):88-91. PubMed ID: 2366570
[TBL] [Abstract][Full Text] [Related]
57. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection.
Pereira A
Haematologica; 2007 Jun; 92(6):846-9. PubMed ID: 17550860
[TBL] [Abstract][Full Text] [Related]
58. Advances in photochemical approaches for blood sterilization.
Ben-Hur E; Horowitz B
Photochem Photobiol; 1995 Sep; 62(3):383-8. PubMed ID: 8570697
[No Abstract] [Full Text] [Related]
59. [Towards bacterial detection in labile blood products].
Morel P
Transfus Clin Biol; 2005 Jun; 12(2):215-20. PubMed ID: 15894499
[TBL] [Abstract][Full Text] [Related]
60. Reducing blood transfusion. Most important transfusion risks go unnoticed by public and politics.
Caspari G; Gerlich WH; Gürtler L
BMJ; 2002 Sep; 325(7365):655. PubMed ID: 12269320
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
